ReviewWorld journal of gastroenterology2016
Differentiation of hepatocellular carcinoma from its various mimickers in liver magnetic resonance imaging: What are the tips when using hepatocyte-specific agents?
Review in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- Abbreviated liver magnetic resonance imaging with a second-shot arterial phase image to assess the viability of treated hepatocellular carcinoma after non-radiation locoregional therapy.Diagnostic and interventional radiology (Ankara, Turkey) · 2026Article
- Comparative analysis of the performance of hepatobiliary agents in depicting MRI features of microvascular infiltration in hepatocellular carcinoma.Abdominal radiology (New York) · 2024Article
- Hepatic perivascular epithelioid cell tumors: The importance of preoperative diagnosis.World journal of gastroenterology · 2024Review
- Intra-patient and inter-observer image quality analysis in liver MRI study with gadoxetic acid using two different multi-arterial phase techniques.The British journal of radiology · 2024Article
- A Rare Red Herring: Intrahepatic Splenosis Masquerading as Hepatocellular Carcinoma.ACG case reports journal · 2023Article
- FI-CEUS: a solution to improve the diagnostic accuracy in MRI LI-RADS-indeterminate (LR-3/4) FLLs at risk for HCC.Frontiers in oncology · 2023Article
- Atypical Manifestation of Primary Hepatocellular Carcinoma and Hepatic Malignancy Mimicking Lesions.Journal of the Korean Society of Radiology · 2022Review
- Liver magnetic resonance imaging: how we do it.Pediatric radiology · 2022Review
- Diffusion-Based Virtual MR Elastography of the Liver: Can It Be Extended beyond Liver Fibrosis?Journal of clinical medicine · 2021Article
- [Consensus on secondary prevention of primary liver cancer (2021 version)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021Article
- Hepatocellular Carcinoma with Macroscopic Fat Metamorphosis: A Case Series.Journal of clinical imaging science · 2021Article
- Intrahepatic splenosis: a world review.Clinical and experimental hepatology · 2020Review
- Patterns of enhancement in the hepatobiliary phase of gadoxetic acid-enhanced MRI.The British journal of radiology · 2020Review
- Gadoxetic acid-enhanced magnetic resonance imaging: Hepatocellular carcinoma and mimickers.Clinical and molecular hepatology · 2019Review
- Second shot arterial phase to overcome degraded hepatic arterial phase in liver MR imaging.European radiology · 2019Article
- Different MR features for differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma according to tumor size.The British journal of radiology · 2018Article
- Magnetic resonance imaging ancillary features used in Liver Imaging Reporting and Data System: An illustrative review.World journal of radiology · 2018Review
- Liver Masses: What Physicians Need to Know About Ordering and Interpreting Liver Imaging.Current gastroenterology reports · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma is the most common primary hepatic malignant tumor. With widespread use of liver imaging, various cirrhosis-related nodules are frequently detected in patients with chronic liver disease, while diverse hypervascular hepatic lesions are incidentally detected but undiagnosed on dynamic computed tomography and magnetic resonance imaging (MRI). However, use of hepatocyte-specific MR contrast agents with combined perfusion and hepatocyte-selective properties have improved diagnostic performance in detection and characterization of focal liver lesions. Meanwhile, the enhancement patterns observed during dynamic phases using hepatocyte-specific agents may be different from those observed during MRI using conventional extracellular fluid agents, leading to confusion in diagnosis. Therefore, we discuss useful tips for the differentiation of hepatocellular carcinoma from similar lesions in patients with and without chronic liver disease using liver MRI with hepatocyte-specific agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.